Exhibit 99.3
PROXYMED, INC.
UNAUDITED PRO FORMA COMBINED STATEMENT OF OPERATIONS
YEAR ENDED DECEMBER 31, 2001
<Table>
<Caption>
Pro Forma
Adjustments
----------------- Pro Forma
ProxyMed, Inc.(a) MedUnite, Inc(b) Total # Dr. (Cr.) Combined
------------ ------------ ------------- ----------------- ------------
Net revenues $ 43,230,000 $ 7,085,000 $ 50,315,000 $ 50,315,000
------------ ------------ ------------- ------------
Costs and expenses:
Cost of sales 20,408,000 1,818,000 22,226,000 22,226,000
Selling, general and adminstrative expenses 21,267,000 46,760,000 68,027,000 68,027,000
Depreciation and amortization 8,176,000 3,036,000 11,212,000 (3) (821,000) 10,672,000
(4) (2,539,000)
(5) 2,820,000
Write-off of impaired assets 91,000 -- 91,000 91,000
----------- ---------- ----------- -----------
49,942,000 51,614,000 101,556,000 101,016,000
----------- ---------- ----------- -----------
Income (loss) from continuing operations (6,712,000) (44,529,000) (51,241,000) (50,701,000)
Other income (expense):
Income from litigation settlement, net 40,000 -- 40,000 40,000
Investment income -- 4,956,000 4,956,000 4,956,000
Interest, net (126,000) (826,000) (952,000) (1) 536,000 (1,319,000)
------------ ------------ ------------- -------------
(2) (169,000)
Income (loss) before income taxes (6,798,000) (40,399,000) (47,197,000) (47,024,000)
Income tax benefit (expense) -- -- -- --
------------ ------------ ------------- -------------
Net income (loss) (6,798,000) (40,399,000) (47,197,000) (47,024,000)
Deemed dividends and other charges 12,262,000 -- 12,262,000 12,262,000
------------ ------------ ------------- -------------
Net loss applicable
to common shareholders $(19,060,000) $(40,399,000) $ (59,459,000) $ (59,286,000)
============ ============ ============= =============
Weighted average common shares outstanding 2,162,352 2,162,352
============ =============
Basic and diluted loss per share of common
stock from continuing operations $ (8.81) $ (27.42)
============ =============
</Table>
(1) To record pro forma interest expense on 4% Convertible Notes issued for
acquisition of MedUnite.
(2) To record elimination of historical interest expense on MedUnite for Founder
and NDCHealth debt cancelled.
(3) To record estimated reduction of depreciation expense on MedUnite based on
adjustment of fixed assets to fair market value.
(4) To reverse historical amortization expense taken on intangible assets
adjusted to fair market value on MedUnite.
(5) To record pro forma amortization expense on intangible assets based on fair
market values for MedUnite.
(a) This column is derived from the audited consolidated financial statements of
ProxyMed, Inc. and subsidiaries for the year ended December 31, 2001.
(b) This column is derived from the audited financial statements of MedUnite
Inc. for the year ended December 31, 2001.
Amounts have been rounded to the nearest $1,000.